HormoneInvestigational

GHRH (Sermorelin 1-44)

Subcutaneous injection

Overview

Sermorelin is a synthetic 44-amino acid peptide corresponding to the biologically active portion of human growth hormone releasing hormone (GHRH). It stimulates endogenous growth hormone secretion from the anterior pituitary by binding to GHRH receptors.

Mechanism of Action

Originally approved for diagnostic testing of growth hormone secretion, sermorelin was subsequently marketed for treatment of growth hormone deficiency in children before being voluntarily withdrawn..

Research Summary & Key Findings

FDA approval was granted in 1997 under the brand name Geref for diagnostic use and later extended to therapeutic indications in pediatric growth hormone deficiency. The manufacturer discontinued sermorelin acetate in the mid-2000s for business reasons unrelated to safety or efficacy. Clinical evidence demonstrated physiologic growth hormone stimulation, though it has been largely supplanted by recombinant growth hormone products.

Clinical Status

Investigational

GHRH (Sermorelin 1-44) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injection

Related Peptides in Hormone

Find a Provider

Find a verified provider who offers GHRH (Sermorelin 1-44) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply GHRH (Sermorelin 1-44).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.